Keyphrases
Natural Killer Cells
92%
Myeloid-derived Suppressor Cells
48%
Interferon-α (IFN-α)
46%
Melanoma
46%
Breast Cancer
44%
Interleukin-12 (IL-12)
35%
Tumor
29%
Interleukin-2
27%
Metastatic Melanoma
25%
T Cells
25%
Melanoma Cells
24%
Tumor Cells
23%
Inflammation
22%
Breast Cancer Survivors
20%
Antitumor Effect
19%
MicroRNA
19%
In Cancer
18%
Cancer Treatment
17%
Interleukin-15 (IL-15)
16%
Tumor Microenvironment
16%
Depressive Symptoms
16%
Malignant Melanoma
14%
Clinical Trials
14%
Trastuzumab
14%
Antitumor Activity
14%
Signal Transduction
14%
Cetuximab
13%
Overall Survival
13%
Fc Receptor
13%
Peripheral Blood Mononuclear Cells
13%
Immune Cells
13%
Interferon alpha-2b
12%
Ibrutinib
12%
Immune Effector Cells
11%
Breast Cancer Patients
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Monocytes
11%
Sentinel Lymph Node Biopsy
11%
Phosphorylation
11%
Bruton's Tyrosine Kinase
11%
Survivors
10%
Paclitaxel
10%
Overexpression
10%
Phase I Study
10%
Triple-negative Breast Cancer
10%
Murine Model
10%
Hazard Ratio
10%
Interleukin-6
10%
Psychological Intervention
10%
Phase I Trial
10%
Immunology and Microbiology
Natural Killer Cell
100%
Immunity
43%
Myeloid-Derived Suppressor Cell
40%
T Cell
35%
Cytokine
31%
Interleukin 2
30%
STAT1
28%
Tumor Cell
27%
Immunocompetent Cell
25%
Immunology
24%
Immunotherapy
23%
Myeloid
20%
Interferon Alfa
20%
Interleukin 12
19%
interferon
18%
Signal Transduction
17%
Interleukin 15
16%
Trastuzumab
15%
Melanoma Cell
15%
Macrophage
13%
Effector Cell
13%
Fc Receptor
13%
Antineoplastic Activity
12%
Gene Expression
11%
Cytotoxicity
11%
Peripheral Blood Mononuclear Cell
11%
Bruton Tyrosine Kinase
10%
Cancer Cell
10%
Cancer Immunotherapy
10%
Melanoma Cell Line
10%
Cetuximab
10%
Overall Survival
9%
T-Helper Cell
9%
Cell Line
9%
Interleukin 6
9%
Stem Cell Factor
8%
Natural Killer Cell Response
8%
B Cell
8%
Cell Population
7%
Lymphocyte
7%
Tumor-Associated Macrophage
7%
Leukemia Cell
7%
Inflammation Response
7%
CD200
7%
Cell Function
7%
Cytotoxic T-Cell
6%
Vasculotropin
6%
Upregulation
6%
Innate Immune System
6%
Interferon Production
6%
Medicine and Dentistry
Breast Cancer
58%
Melanoma
48%
Neoplasm
44%
Malignant Neoplasm
39%
Myeloid-Derived Suppressor Cell
30%
Immunity
18%
microRNA
17%
Immunotherapy
17%
Interferon Alfa
16%
Natural Killer Cell
15%
Metastatic Melanoma
14%
Disease
13%
Tumor Microenvironment
12%
In Vitro
12%
T Cell
12%
Melanoma Cell
12%
Bruton Tyrosine Kinase
11%
Surgery
11%
Signal Transduction
11%
Tumor Cell
10%
Cytokine
10%
Ibrutinib
10%
Sentinel Lymph Node Biopsy
10%
Melanoma Cell Line
9%
Overall Survival
9%
Depression
9%
Chemotherapy
9%
Clinical Trial
9%
Interferon
8%
Metastatic Carcinoma
8%
Immunocompetent Cell
8%
Myeloid Cell
8%
Triple Negative Breast Cancer
8%
Randomized Clinical Trial
8%
Biological Marker
8%
Oncology
8%
T-Helper Cell
7%
Recurrent Disease
7%
Cutaneous Melanoma
7%
Interferon Alfa 2b
7%
Peripheral Blood Mononuclear Cell
7%
Adjuvant Therapy
7%
Mastectomy
7%
Macrophage
6%
Programmed Cell Death
6%
Neoadjuvant Chemotherapy
6%
Cancer
6%
Nitric Oxide
6%
Effector Cell
6%
Cell Population
6%
